MAZE
HealthcareMaze Therapeutics, Inc. · Biotechnology · $1B
What is Maze Therapeutics, Inc.?
Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule precision medicines targeting kidney disease, cardiovascular conditions, metabolic disorders, and obesity. The company is based in South San Francisco, California.
Maze Therapeutics applies a precision medicine approach to diseases with well-defined genetic drivers. The company generates no product revenue at this stage — its value lies entirely in its clinical pipeline. Lead program MZE829 targets APOL1 kidney disease through inhibition of apolipoprotein L1, currently in Phase II trials. A second candidate, MZE782, inhibits the solute transporter SLC6A19 and is in Phase I trials for chronic kidney disease. Both are oral small molecules, a formulation advantage over injectable biologics.
Incorporated in 2017 and formerly known as Modulus Therapeutics, the company rebranded as Maze Therapeutics in September 2018.
- MZE829 — oral APOL1 inhibitor in Phase II for APOL1 kidney disease
- MZE782 — oral SLC6A19 inhibitor in Phase I for chronic kidney disease
- Precision medicine platform targeting genetically defined patient populations
- Pipeline focus on renal, cardiovascular, and metabolic disease
Is MAZE a Good Stock to Buy?
UQS Score rates MAZE as Poor overall, reflecting the early-stage nature of its pipeline and the significant uncertainties that come with pre-revenue drug development.
The one area where MAZE stands out relative to its profile is Risk, which earns a Good label — suggesting the company's balance sheet and near-term financial structure are more stable than its overall score might imply. This is not uncommon for clinical-stage biotechs that have raised sufficient cash to fund operations.
Quality, Moat, Growth, and Valuation all register as Weak or Elevated, reflecting the absence of revenue, an unproven competitive position, and a market price that may not yet account for pipeline risk.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MAZE pay dividends?
No — Maze Therapeutics, Inc. does not currently pay a dividend.
MAZE does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. All available capital is directed toward funding clinical trials and advancing the pipeline. Investors in companies like Maze are typically seeking long-term value creation through drug approvals rather than income.
When does MAZE report earnings?
Maze Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, quarterly reports focus primarily on cash runway, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Pipeline milestones and trial readouts tend to move the stock more than earnings beats or misses.
For the most recent quarter's results and cash position updates, visit Maze Therapeutics' investor relations page directly.
MAZE Price History
+61.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Maze Therapeutics, Inc.?
Based on Maze Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
MAZE Long-term Outlook
The fundamental outlook for MAZE is shaped almost entirely by clinical trial outcomes. With Growth and Quality both rated Weak, the near-term trajectory depends on whether MZE829 and MZE782 generate positive data. A Good Risk rating suggests the company has some financial runway, but the Elevated Valuation label indicates the market may already be pricing in optimistic scenarios. Investors should weigh binary trial risk carefully against the potential upside of a successful readout in a genetically defined patient population.
Growth drivers
- Positive Phase II data for MZE829 in APOL1 kidney disease
- Advancement of MZE782 through Phase I and into later-stage trials
- Growing clinical and commercial interest in precision renal medicine
Key risks
- Clinical trial failure or disappointing efficacy data
- Elevated valuation relative to pre-revenue pipeline stage
- Capital needs and potential dilution from future fundraising
MAZE vs Peers
Maze Therapeutics operates in a competitive clinical-stage biotech landscape alongside other small-cap companies pursuing novel therapeutic mechanisms.
Wave Life Sciences focuses on RNA-based medicines, pursuing a distinct molecular modality compared to Maze's oral small molecule approach.
Corvus Pharmaceuticals targets immuno-oncology, giving it a different disease focus and competitive dynamic than Maze's renal and metabolic pipeline.
Novavax is a vaccine-focused company with commercial products already on the market, representing a more advanced stage of development than Maze.
Frequently Asked Questions
What does Maze Therapeutics do?
Maze Therapeutics develops oral small molecule precision medicines targeting kidney disease, cardiovascular conditions, metabolic disorders, and obesity. Its two lead programs are in active clinical trials — one in Phase II and one in Phase I — both focused on genetically defined patient populations with high unmet medical need.
Does MAZE pay dividends?
No, MAZE does not pay a dividend. As a clinical-stage company with no product revenue, Maze directs all capital toward funding its research and clinical programs. Dividend payments are not typical for pre-revenue biotechs at this stage of development.
When does MAZE report earnings?
Maze Therapeutics follows a standard quarterly reporting schedule for US-listed companies. Because it has no product revenue, reports focus on operating expenses and cash runway. For exact dates, check the investor relations section of the Maze Therapeutics website.
Is MAZE a good stock to buy?
UQS Score rates MAZE as Poor overall, driven by Weak scores across Quality, Moat, and Growth pillars, alongside an Elevated Valuation. The Good Risk rating offers some reassurance about near-term financial stability, but the overall profile reflects the high uncertainty typical of early-stage drug development. The full pillar breakdown is available to Pro members.
Is MAZE overvalued?
The UQS Valuation pillar for MAZE is rated Elevated, suggesting the current market price may not fully reflect the binary risks embedded in a pre-revenue clinical pipeline. Valuation for clinical-stage biotechs is inherently speculative and tied to trial outcomes rather than current fundamentals.
How does MAZE compare to its competitors?
Compared to peers like Wave Life Sciences, Corvus Pharmaceuticals, and Novavax, Maze is distinguished by its oral small molecule approach and focus on genetically defined renal disease. Each competitor pursues different modalities and disease areas, making direct comparison complex. The UQS platform provides side-by-side scoring for a more structured view.
What is MAZE's market cap bracket?
MAZE is classified as a small-cap stock. This is consistent with its clinical-stage status — most pre-revenue biopharmaceutical companies carry smaller market capitalizations that reflect pipeline potential rather than current business scale.
Who founded Maze Therapeutics?
Maze Therapeutics was incorporated in 2017 under the name Modulus Therapeutics before rebranding in 2018. Founding details and leadership history are publicly available on the company's website and in SEC filings for investors seeking background on the management team.
Is MAZE a long-term quality investment?
As a long-term quality indicator, MAZE's UQS Score of Poor reflects meaningful structural weaknesses — particularly the absence of revenue, an unproven moat, and limited growth visibility. Long-term quality typically requires demonstrated earnings power and competitive durability, neither of which MAZE has established yet. Clinical success could change this picture materially.
What is the main competitive advantage of Maze Therapeutics?
Maze's differentiation lies in its precision medicine platform, which targets patients with specific genetic variants driving their disease. This approach — particularly in APOL1 kidney disease — allows for more defined patient selection. However, the UQS Moat pillar rates this advantage as Weak until clinical and commercial validation is achieved.
Is MAZE a growth stock or value stock?
Based on UQS pillar labels, MAZE carries an Elevated Valuation and a Weak Growth rating — an unfavorable combination. It does not fit the profile of a traditional growth stock with demonstrated revenue expansion, nor a value stock with depressed multiples relative to earnings. It is best characterized as a speculative clinical-stage biotech.
Unlock Full MAZE Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics and trend data
- ✓Compare MAZE against peers on a standardized scoring system
- ✓Track Quality, Moat, Risk, and Valuation signals in one place
- ✓Get the full analyst view available only to Pro members
Pro Analysis
MAZE — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | 12.3 | 0.0 | 11.0 | 0.0 | 63.7 | 0.0 | +2.6 |
| May 9, 2026 | 9.7 | 0.0 | 11.0 | 0.0 | 46.2 | 0.0 | -2.6 |
| Apr 4, 2026 | 12.3 | 0.0 | 11.0 | 0.0 | 63.7 | 0.0 | -0.1 |
| Apr 2, 2026 | 12.4 | 0.0 | 11.0 | 0.0 | 64.2 | 0.0 | — |
MAZE — Pillar Breakdown
Quality
— 0.0/100 (25%)Maze Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Maze Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 65.0/100 (15%)Maze Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Maze Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Maze Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MAZE.
Score Composition
Financial Data
More Stock Analysis
How is the MAZE UQS Score Calculated?
The UQS (Unified Quality Score) for Maze Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Maze Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Maze Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.